Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AD17002 in House Dust Mite Allergic Rhinitis
NCT04088721Phase 2Completed
- Sponsor
- Advagene Biopharma Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AD-17002 in house dust mite allergic rhinitis, sponsored by Advagene Biopharma Co., Ltd.. Started Mar 2019; status: completed.
02
Drugs
AD-17002
03
Conditions
house dust mite allergic rhinitis
Beyond the preview
Go deeper on NCT04088721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088721.